BenzingaSeptember 24, 2026 at 4:56 AM NYLast Month
Goldman Sachs Reinstates Buy on Krystal Biotech, Announces $441 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Krystal Biotech (NASDAQ:KRYS) with a Buy and announces $441 price target.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
